Current pharmacological treatments for non-TNBC breast cancers include tamoxifen, a competitive inhibitor of the estrogen receptor; aromatase inhibitors, which target the enzyme that performs the last step of estrogen biosynthesis; and trastuzumab, which binds the HER2 receptor [7,8]. This evidence concerns the gene ESR1 and breast carcinoma.